James Shaochi Hwong, MD
Urology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 32
- 8 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
32 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Hwong’s office at (408) 871-5080 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
32 of 32 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A149247 · Current
Licensed to practise in California · since 2017 · expires 2028-07-31 · Northwestern University Feinberg School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$153,849
Medicare paid this office $153,849 for 267 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 180 | $34,142 | $111 |
| New patient visit (45+ min) | 100 | $14,003 | $140 |
| Diagnostic exam of bladder and urethra using an endoscope | 36 | $9,054 | $216 |
| Long return visit (40+ min) | 26 | $6,118 | $161 |
| Ultrasound scan of pelvic region through rectum | 17 | $2,530 | $149 |
See all 9 services
| Return visit (30+ min) | 180 | $34,142 | $111 |
| New patient visit (45+ min) | 100 | $14,003 | $140 |
| Diagnostic exam of bladder and urethra using an endoscope | 36 | $9,054 | $216 |
| Long return visit (40+ min) | 26 | $6,118 | $161 |
| Ultrasound scan of pelvic region through rectum | 17 | $2,530 | $149 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 108 | $2,092 | $15 |
| Urinalysis, manual test | 191 | $989 | $3 |
| Ultrasound measurement of bladder capacity after voiding | 35 | $473 | $12 |
| Manual urinalysis test with examination using microscope, non-automated | 45 | $181 | $4 |
Procedures Medicare counted
| Prostate resection | 15 | More than 70% of doctors who do this |
Who their Medicare patients are
267 Original Medicare patients in 2024. Average age 76 · Under 65 6% · 85 and older 15% · Women 17% · Also on Medicaid 55% · Health risk score 1.40. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Diabetes 51% · Chronic kidney disease 34% · Cancer 34% · Coronary heart disease 28% · Atrial fibrillation 15% · Heart failure 12% · COPD 12% · Depression 11% · Dementia 8% · Stroke 6%.
The office billed $618,816, Medicare allowed $200,999 and paid $153,849; for 4,102 services of 60 kinds; $47,603 of it was for drugs given in the office and $106,247 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 267 | 4,102 | 76 | 1.40 | $618,816 | $153,849 |
| 2023 | 233 | 3,872 | 76 | 1.19 | $434,069 | $170,112 |
| 2022 | 234 | 3,925 | 74 | 1.26 | $515,302 | $189,043 |
| 2021 | 221 | 4,595 | 75 | 1.62 | $443,181 | $178,409 |
| 2020 | 226 | 3,674 | 74 | 1.80 | $479,138 | $172,621 |
| 2019 | 263 | 1,713 | 75 | 1.43 | $556,719 | $187,824 |
| 2018 | 183 | 590 | 75 | 1.58 | $179,106 | $49,224 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 181 | $35,825 | $109 |
| Diagnostic exam of bladder and urethra using an endoscope | 40 | $9,421 | $205 |
| New patient visit (45+ min) | 53 | $7,666 | $145 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 16 | $6,185 | $387 |
| Long return visit (40+ min) | 21 | $5,332 | $167 |
| Ultrasound scan of pelvic region through rectum | 26 | $3,712 | $143 |
| Short return visit (20+ min) | 15 | $1,184 | $74 |
| Manual urinalysis test with examination using microscope, non-automated | 179 | $1,020 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 21 | $316 | $12 |
| Electronic assessment of bladder emptying | 16 | $108 | $7 |
2022: 12 services
| Return visit (30+ min) | 167 | $33,914 | $109 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 27 | $10,662 | $395 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $9,892 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 37 | $7,420 | $177 |
| New patient visit (45+ min) | 56 | $7,399 | $132 |
| Long return visit (40+ min) | 16 | $3,100 | $155 |
| Ultrasound scan of pelvic region through rectum | 21 | $2,978 | $142 |
| Short return visit (20+ min) | 26 | $2,015 | $72 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $1,018 | $33 |
| Manual urinalysis test with examination using microscope, non-automated | 178 | $989 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 31 | $402 | $10 |
| Electronic assessment of bladder emptying | 29 | $187 | $6 |
2021: 11 services
| Return visit (30+ min) | 160 | $40,298 | $117 |
| Diagnostic exam of bladder and urethra using an endoscope | 43 | $9,475 | $193 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 23 | $9,198 | $400 |
| New patient visit (45+ min) | 60 | $8,742 | $146 |
| Short return visit (20+ min) | 34 | $2,879 | $74 |
| Ultrasound scan of pelvic region through rectum | 14 | $2,117 | $151 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,612 | $124 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $1,238 | $34 |
| Manual urinalysis test with examination using microscope, non-automated | 161 | $1,041 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 49 | $611 | $11 |
| Electronic assessment of bladder emptying | 31 | $246 | $8 |
2020: 12 services
| Return visit (30+ min) | 152 | $28,387 | $94 |
| New patient visit (45+ min) | 65 | $9,101 | $140 |
| Diagnostic exam of bladder and urethra using an endoscope | 38 | $7,362 | $180 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 16 | $5,645 | $353 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,509 | $185 |
| Ultrasound scan of pelvic region through rectum | 12 | $1,685 | $140 |
| Short return visit (20+ min) | 18 | $1,633 | $65 |
| New patient visit (30+ min) | 16 | $1,455 | $91 |
| Manual urinalysis test with examination using microscope, non-automated | 150 | $958 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 43 | $555 | $10 |
| Electronic assessment of bladder emptying | 26 | $236 | $9 |
| Manual urinalysis test with examination using microscope, automated | 12 | $47 | $3 |
2019: 16 services
| Return visit (30+ min) | 148 | $31,318 | $100 |
| New patient visit (45+ min) | 95 | $12,859 | $135 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 29 | $10,841 | $350 |
| Diagnostic exam of bladder and urethra using an endoscope | 60 | $10,776 | $158 |
| Ultrasound scan of pelvic region through rectum | 31 | $4,145 | $134 |
| Short return visit (20+ min) | 38 | $3,953 | $67 |
| Biopsy of prostate gland | 15 | $3,749 | $250 |
| Long return visit (40+ min) | 21 | $3,611 | $139 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,976 | $124 |
| New patient visit (30+ min) | 15 | $1,409 | $94 |
| Manual urinalysis test with examination using microscope, non-automated | 178 | $1,289 | $4 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,256 | $66 |
| Ultrasound measurement of bladder capacity after voiding | 56 | $1,043 | $12 |
| Ultrasonic guidance for needle placement | 16 | $953 | $56 |
| Imaging of urinary tract following injection of a contrast agent | 19 | $547 | $24 |
| Electronic assessment of bladder emptying | 52 | $492 | $8 |
2018: 9 services
| New patient visit (45+ min) | 64 | $9,437 | $147 |
| Return visit (30+ min) | 60 | $7,258 | $99 |
| Diagnostic exam of bladder and urethra using an endoscope | 16 | $2,529 | $158 |
| Short return visit (20+ min) | 31 | $2,423 | $69 |
| Long return visit (40+ min) | 16 | $2,183 | $136 |
| New patient visit (30+ min) | 19 | $1,829 | $96 |
| Manual urinalysis test with examination using microscope, non-automated | 89 | $394 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 19 | $353 | $17 |
| Manual urinalysis test with examination using microscope, automated | 25 | $119 | $4 |
Medicaid work
$966 in 2024
Medicaid paid $966 for 623 billed services this clinician did in 2024, up to 33 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 250 | $949 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 48 | $12 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 190 | $6 |
| Medication list documented in medical record (COA) | 62 | $0 |
| Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record (COA) | 16 | $0 |
| New patient visit (45+ min) | 57 | $0 |
| 2024 | 623 | 6 | 33 | $966 |
| 2023 | 714 | 3 | 36 | $3,544 |
| 2022 | 576 | 3 | 33 | $1,124 |
| 2021 | 663 | 4 | 40 | $693 |
| 2020 | 437 | 3 | 33 | $605 |
| 2019 | 254 | 3 | 25 | $63 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 328 | $3,161 |
| New patient visit (45+ min) | 46 | $293 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 340 | $90 |
2022
| Return visit (30+ min) | 270 | $974 |
| New patient visit (45+ min) | 12 | $105 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 294 | $45 |
2021
| Return visit (30+ min) | 282 | $467 |
| New patient visit (45+ min) | 49 | $201 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 320 | $24 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 12 | $2 |
2020
| Return visit (30+ min) | 216 | $589 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 196 | $16 |
| New patient visit (45+ min) | 25 | $0 |
2019
| Return visit (30+ min) | 155 | $43 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 86 | $20 |
| New patient visit (45+ min) | 13 | $0 |
Drugs they prescribed that Part D paid
$1,724,828
Pharmacies billed $1,724,828 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,370 generic and 512 brand-name prescriptions · $1,724,828 in drug cost · 176 antibiotic prescriptions to 141 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 52 | $624,154 | $12,003 |
| Erleada | 39 | $536,388 | $13,754 |
| Orgovyx | 131 | $345,166 | $2,635 |
| Gemtesa | 247 | $170,920 | $692 |
| Myrbetriq | 40 | $23,715 | $593 |
See all 14 drugs
| Xtandi | 52 | $624,154 | $12,003 |
| Erleada | 39 | $536,388 | $13,754 |
| Orgovyx | 131 | $345,166 | $2,635 |
| Gemtesa | 247 | $170,920 | $692 |
| Myrbetriq | 40 | $23,715 | $593 |
| Tamsulosin | 717 | $8,781 | $12 |
| Oxybutynin Chloride Er | 191 | $4,957 | $26 |
| Potassium Citrate Er | 19 | $2,918 | $154 |
| Finasteride | 141 | $1,978 | $14 |
| Bethanechol Chloride | 12 | $1,065 | $89 |
| Ciprofloxacin | 132 | $400 | $3 |
| Doxazosin Mesylate | 25 | $308 | $12 |
| Oxybutynin Chloride | 14 | $194 | $14 |
| Sulfamethoxazole-Trimethoprim | 29 | $83 | $3 |
Year by year
| 2024 | 1,882 | 510 | None | 27% | $1,724,828 |
| 2023 | 1,523 | 458 | 1% (15) | 15% | $1,246,098 |
| 2022 | 1,274 | 421 | 1% (17) | 14% | $1,013,153 |
| 2021 | 1,001 | 339 | 2% (18) | 11% | $364,983 |
| 2020 | 918 | 293 | 2% (19) | None | $650,280 |
| 2019 | 644 | 244 | 3% (20) | 10% | $144,168 |
| 2018 | 423 | 180 | None | 16% | $36,094 |
| 2017 | 117 | 53 | None | 15% | $8,757 |
| 2016 | 66 | 36 | 35% (23) | None | $2,566 |
| 2015 | 83 | 60 | 34% (28) | None | $2,402 |
| 2014 | 106 | 64 | 35% (37) | None | $1,503 |
| 2013 | 101 | 65 | 43% (43) | None | $2,958 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Erleada | 39 | $636,280 | $16,315 |
| Xtandi | 16 | $322,997 | $20,187 |
| Orgovyx | 55 | $144,794 | $2,633 |
| Gemtesa | 59 | $56,935 | $965 |
| Myrbetriq | 56 | $36,643 | $654 |
| Tamsulosin | 627 | $16,631 | $27 |
| Oxybutynin Chloride Er | 215 | $12,090 | $56 |
| Potassium Citrate Er | 17 | $4,748 | $279 |
| Finasteride | 94 | $2,488 | $26 |
| Ciprofloxacin | 154 | $741 | $5 |
| Doxazosin Mesylate | 21 | $678 | $32 |
| Bicalutamide | 20 | $655 | $33 |
| Terazosin | 12 | $396 | $33 |
| Sulfamethoxazole-Trimethoprim | 39 | $208 | $5 |
2022: 13 drugs
| Erleada | 46 | $669,652 | $14,558 |
| Xtandi | 17 | $218,733 | $12,867 |
| Myrbetriq | 71 | $43,307 | $610 |
| Gemtesa | 30 | $32,528 | $1,084 |
| Oxybutynin Chloride Er | 184 | $12,398 | $67 |
| Tamsulosin | 490 | $11,711 | $24 |
| Potassium Citrate Er | 21 | $3,553 | $169 |
| Finasteride | 68 | $1,977 | $29 |
| Ciprofloxacin | 160 | $697 | $4 |
| Doxazosin Mesylate | 14 | $293 | $21 |
| Amoxicillin-Clavulanate Potass | 11 | $178 | $16 |
| Sulfamethoxazole-Trimethoprim | 39 | $165 | $4 |
| Oxycodone-Acetaminophen | 15 | $85 | $6 |
2021: 13 drugs
| Xtandi | 14 | $170,215 | $12,158 |
| Myrbetriq | 48 | $26,132 | $544 |
| Toviaz | 23 | $11,307 | $492 |
| Oxybutynin Chloride Er | 156 | $10,660 | $68 |
| Tamsulosin | 398 | $7,756 | $19 |
| Testosterone | 12 | $5,244 | $437 |
| Potassium Citrate Er | 17 | $3,034 | $178 |
| Finasteride | 46 | $1,332 | $29 |
| Ciprofloxacin | 134 | $562 | $4 |
| Doxazosin Mesylate | 11 | $242 | $22 |
| Oxybutynin Chloride | 12 | $207 | $17 |
| Sulfamethoxazole-Trimethoprim | 24 | $72 | $3 |
| Oxycodone-Acetaminophen | 13 | $62 | $5 |
2020: 15 drugs
| Xtandi | 34 | $419,868 | $12,349 |
| Myrbetriq | 31 | $17,579 | $567 |
| Toviaz | 14 | $14,125 | $1,009 |
| Solifenacin | 15 | $7,745 | $516 |
| Oxybutynin Chloride Er | 138 | $6,943 | $50 |
| Potassium Citrate Er | 30 | $4,975 | $166 |
| Tamsulosin | 300 | $4,496 | $15 |
| Finasteride | 42 | $936 | $22 |
| Nitrofurantoin Mono-Macro | 19 | $917 | $48 |
| Bicalutamide | 12 | $817 | $68 |
| Ciprofloxacin | 126 | $507 | $4 |
| Alendronate | 14 | $176 | $13 |
| Terazosin | 12 | $165 | $14 |
| Sulfamethoxazole-Trimethoprim | 29 | $112 | $4 |
| Oxycodone-Acetaminophen | 14 | $84 | $6 |
2019: 13 drugs
| Myrbetriq | 13 | $9,793 | $753 |
| Toviaz | 11 | $6,593 | $599 |
| Oxybutynin Chloride Er | 88 | $6,074 | $69 |
| Potassium Citrate Er | 17 | $3,923 | $231 |
| Tamsulosin | 175 | $3,053 | $17 |
| Finasteride | 46 | $1,468 | $32 |
| Bicalutamide | 25 | $1,006 | $40 |
| Nitrofurantoin Mono-Macro | 21 | $941 | $45 |
| Ciprofloxacin | 111 | $563 | $5 |
| Alendronate | 16 | $262 | $16 |
| Sulfamethoxazole-Trimethoprim | 16 | $80 | $5 |
| Oxycodone-Acetaminophen | 12 | $39 | $3 |
| Lorazepam | 23 | $16 | $1 |
2018: 9 drugs
| Vesicare | 16 | $7,417 | $464 |
| Tamsulosin | 130 | $2,633 | $20 |
| Oxybutynin Chloride Er | 42 | $2,007 | $48 |
| Finasteride | 71 | $1,930 | $27 |
| Methenamine Hippurate | 11 | $515 | $47 |
| Bicalutamide | 11 | $375 | $34 |
| Ciprofloxacin | 18 | $109 | $6 |
| Terazosin | 11 | $76 | $7 |
| Sulfamethoxazole-Trimethoprim | 14 | $68 | $5 |
2017: 2 drugs
| Tamsulosin | 36 | $700 | $19 |
| Finasteride | 26 | $506 | $19 |
2016: 2 drugs
| Tamsulosin | 13 | $180 | $14 |
| Oxycodone | 21 | $117 | $6 |
2015: 3 drugs
| Tamsulosin | 13 | $347 | $27 |
| Oxycodone | 28 | $178 | $6 |
| Ciprofloxacin | 21 | $67 | $3 |
2014: 4 drugs
| Tamsulosin | 14 | $225 | $16 |
| Hydrocodone-Acetaminophen | 21 | $151 | $7 |
| Oxycodone | 13 | $116 | $9 |
| Ciprofloxacin | 14 | $57 | $4 |
2013: 2 drugs
| Oxycodone | 40 | $266 | $7 |
| Ciprofloxacin | 11 | $55 | $5 |
Money from drug and device companies
$1,051 in 2025
| 2025 | 10 | 34 | None | $1,051 |
| 2024 | 11 | 33 | None | $994 |
| 2023 | 9 | 26 | None | $827 |
| 2022 | 10 | 26 | None | $677 |
| 2021 | 9 | 23 | None | $607 |
| 2020 | 9 | 26 | None | $3,575 |
| 2019 | 10 | 62 | $2,000 | $4,280 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sumitomo Pharma America | Gemtesa | $378 | 10 payments
|
| Ferring Pharmaceuticals | Adstiladrin | $291 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $95 | 3 payments
|
| Janssen Biotech | Erleada | $55 | 2 payments
|
| Astellas Pharma US | Xtandi | $53 | 2 payments
|
| Accord Healthcare | Camcevi | $44 | 2 payments
|
See all 34 published payments
| Abbvie | Meals · 2025-12-15 | Lupron Depot | $15 |
| Ferring Pharmaceuticals | Meals · 2025-12-04 | Adstiladrin | $7 |
| Ferring Pharmaceuticals | Meals · 2025-12-03 | Adstiladrin | $25 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-05 | Nubeqa | $14 |
| Sumitomo Pharma America | Meals · 2025-10-30 | Gemtesa | $7 |
| Ferring Pharmaceuticals | Meals · 2025-10-08 | Adstiladrin | $28 |
| Sumitomo Pharma America | Meals · 2025-09-29 | Gemtesa | $39 |
| Pfizer | Meals · 2025-09-24 | Xtandi | $28 |
| Sumitomo Pharma America | Meals · 2025-08-27 | Orgovyx | $145 |
| Sumitomo Pharma America | Meals · 2025-08-24 | Gemtesa | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-22 | None | $31 |
| Ferring Pharmaceuticals | Meals · 2025-08-21 | Adstiladrin | $16 |
| Ferring Pharmaceuticals | Meals · 2025-08-20 | Adstiladrin | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-08 | None | $34 |
| Sumitomo Pharma America | Meals · 2025-07-28 | Gemtesa | $17 |
| Accord Healthcare | Meals · 2025-07-10 | Camcevi | $22 |
| Ferring Pharmaceuticals | Meals · 2025-07-02 | Adstiladrin | $37 |
| Sumitomo Pharma America | Meals · 2025-06-29 | Gemtesa | $37 |
| Janssen Biotech | Meals · 2025-06-25 | Erleada | $34 |
| Sumitomo Pharma America | Meals · 2025-06-19 | Gemtesa | $26 |
| Sumitomo Pharma America | Meals · 2025-06-11 | Gemtesa | $44 |
| Sumitomo Pharma America | Meals · 2025-06-03 | Gemtesa | $14 |
| Abbvie | Meals · 2025-05-21 | Lupron Depot | $23 |
| Accord Healthcare | Meals · 2025-05-08 | Camcevi | $22 |
| Ferring Pharmaceuticals | Meals · 2025-05-01 | Adstiladrin | $18 |
| Ferring Pharmaceuticals | Meals · 2025-05-01 | Adstiladrin | $26 |
| Ferring Pharmaceuticals | Meals · 2025-04-23 | Adstiladrin | $116 |
| Progenics Pharmaceuticals | Meals · 2025-04-09 | Pylarify | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-07 | Lynparza | $31 |
| Astellas Pharma US | Meals · 2025-03-26 | Xtandi | $29 |
| Astellas Pharma US | Meals · 2025-02-19 | Xtandi | $24 |
| Sumitomo Pharma America | Meals · 2025-02-06 | Gemtesa | $25 |
| Janssen Biotech | Meals · 2025-02-05 | Erleada | $21 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-29 | Nubeqa | $27 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $994
| Janssen Biotech | Erleada | $209 | 7 payments
|
| Accord Healthcare | Camcevi | $131 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $118 | 4 payments
|
| Astellas Pharma US | Xtandi | $105 | 3 payments
|
| Sumitomo Pharma America | Gemtesa | $102 | 3 payments
|
| Pfizer | Xtandi | $100 | 4 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $79 | 3 payments
|
| Boston Scientific | Rezum Generator | $74 | 2 payments
|
| Axonics | Axonics | $30 | 1 payment
|
| Coloplast | Luja Coude | $26 | 1 payment
|
| Olympus America | Itind System | $20 | 1 payment
|
2023: $827
| Sumitomo Pharma America | Gemtesa | $213 | 7 payments
|
| Janssen Biotech | Erleada | $187 | 6 payments
|
| Edap Technomed | None | $125 | 1 payment
|
| Astellas Pharma US | Xtandi | $96 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $68 | 3 payments
|
| Pfizer | Xtandi | $58 | 3 payments
|
| Amgen | Xgeva | $32 | 1 payment
|
| Boston Scientific | Rezum Generator | $31 | 1 payment
|
| Accord Healthcare | Camcevi | $16 | 1 payment
|
2022: $677
| Janssen Biotech | Erleada | $146 | 5 payments
|
| Urovant Sciences | Gemtesa | $122 | 6 payments
|
| Teleflex | Urolift | $121 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $82 | 4 payments
|
| Boston Scientific | Rezum Generator | $51 | 2 payments
|
| Astellas Pharma US | Xtandi | $48 | 2 payments
|
| Amgen | Xgeva | $34 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $29 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $28 | 1 payment
|
| Olympus America | Itind System | $16 | 1 payment
|
2021: $607
| Janssen Biotech | Erleada | $185 | 5 payments
|
| Urovant Sciences | Gemtesa | $177 | 7 payments
|
| Astellas Pharma US | Xtandi | $97 | 4 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $39 | 2 payments
|
| Amgen | Xgeva | $26 | 1 payment
|
| Boston Scientific | General Bph | $22 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $21 | 1 payment
|
| SRS Medical Systems | Urocuff | $21 | 1 payment
|
| Teleflex | Urolift System | $19 | 1 payment
|
2020: $3,575
| Intuitive Surgical | Da Vinci Surgical System | $3,000 | 1 payment
|
| Astellas Pharma US | Myrbetriq | $260 | 8 payments
|
| Pfizer | Xtandi | $115 | 9 payments
|
| Janssen Biotech | Erleada | $80 | 3 payments
|
| NeoTract | Urolift | $30 | 1 payment
|
| Boston Scientific | Swiss Lithoclast Trilogy | $30 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $25 | 1 payment
|
| Photocure | Cysview | $18 | 1 payment
|
| Ferring Pharmaceuticals | Firmagon | $18 | 1 payment
|
2019: $4,280
| NeoTract | Urolift | $3,015 | 11 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $281 | 1 payment
|
| Pfizer | Xtandi | $247 | 19 payments
|
| Janssen Biotech | Erleada | $244 | 10 payments
|
| Astellas Pharma US | Xtandi | $206 | 8 payments
|
| Boston Scientific | General Bph | $122 | 6 payments
|
| Dendreon Pharmaceuticals | Provenge | $59 | 2 payments
|
| Allergan | Botox | $44 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $34 | 2 payments
|
| AngioDynamics | None | $27 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1629335476
- Licence
- CA A149247California A149247: Current · expires 2028-07-31
- Trained
- Northwestern University Feinberg Medical School, 2012
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X); Student in a training program (390200000X)
- Mailing address
- 5767 W Century Blvd Ste 400, Los Angeles, CA, 90045
- NPI first listed
- 2012-04-18
- NPI last updated
- 2022-07-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 75 Francis St, Boston, MA, 02115